All In Biotech

Drug Trial Radar · NCT07790640

Evaluate the Efficacy and Safety of CTO0308 in Pediatric Patients With Myopia

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-design, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CTO0308 in Pediatric Patients With Myopia

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 351 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

351

Actual

Start

Aug 11, 2025

Primary completion

Apr 1, 2027

Study completion Sep 1, 2027

Sponsor

Sponsor type
Industry
First posted
Aug 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 5 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was to evaluate the superiority of the myopia progression control effect in the treatment group compared with the control group, evaluated by the change in spherical equivalent (SE) after 12 months of administration of the investigational product.

Conditions

  • Myopia

Interventions

  • CTO0308Drug

    Ophthalmic solution, one drop in each eye, once daily

  • Vehicle (Placebo solution)Drug

    Vehicle, one drop in each eye, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Spherical Equivalent (SE)Time frame: Month 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Gachon University Gil Medical Center

    Incheon, Incheon, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.